INTRODUCTION AND OBJECTIVES:
The micropapillary variant of urothelial carcinoma, originally described in 1994, has been shown to be aggressive and associated with poorer outcomes. Early studies reported incidence rates of 0.7-2.2%. Our hypothesis is that as detection and awareness of this histological variant has increased, survival outcomes would improve in more recent time periods.
METHODS: A retrospective chart review of patients treated with radical cystectomy and pathologic T2 bladder and above with micropapillary histology at our institution was performed from 2008-2017. Populations were grouped based on surgery year (2008 -2011; 2012-2014; 2015-2017) to evaluate trends over time. A cohort of patients diagnosed with pure urothelial carcinoma during this time frame was included as a comparator arm. The primary outcome was cancerspecific survival. Secondary outcomes included the overall percentage of micropapillary versus overall urothelial histology, and overall survival.
RESULTS: A total of 486 patients were included in this analysis, with 76 micropapillary and 410 pure urothelial patients. Median follow up time was 24.9 months. In the micropapillary cohort, 35/76 (46.1%) received neoadjuvant chemotherapy, with overall cancer specific survival (CSS) of 67.1%. When comparing demographics based on year of surgery, the proportion of the micropapillary variant has increased over time (p[0.0054, figure 1) CONCLUSIONS: With increasing rates of diagnosis of variant histology over time, it was expected the more recent cohort would have better survival outcomes due to increased identification alone. However, our results showed no significant difference in outcomes grouped by year of diagnosis. A potential confounder could be increased comorbidities of the more recent cohort, increasing receipt of NAC, and shorter follow-up. Further studies are recommended to evaluate the evolution of this diagnosis over time. METHODS: Using immune infiltration markers that are known to have prognostic value in multiple solid tumors, the existence of immune subtypes were evaluated within each molecular subtype (basal, luminal and p53-like) in TCGA cohort. The potential therapeutic significance of these novel immune subtypes on chemotherapy response was evaluated using public data consisting of patients who received neoadjuvant chemotherapy (NAC) followed by radical cystectomy (NAC cohort). Stromal cell infiltration within each molecular subtype was estimated using the recently developed CIBERSORT tool.
RESULTS: Our analysis identified two novel immune subtypes within basal tumors (basal immune signature enriched; BIE and basal immune signature suppressed; BIS). BIE had significantly improved survival outcomes while BIS still remained the subtype with the worst survival outcomes among MIBC patients in the TCGA cohort (n[408). Though Immune signature enriched tumors were also identified within p53-like subtype, no survival benefit in these tumors was observed. The characterization of the immune landscape in our novel subtypes using TCGA recent pan-cancer immunogenomics data showed that the BIE subtype was significantly enriched with gene expression signatures that are characteristic of tumor infiltrating lymphocytes and active IFN-[gamma] signaling (p<0.05). Among patients who received NAC followed by radical cystectomy (NAC cohort), those with BIE tumors were the most responsive to chemotherapy while patients with BIS and p53-like tumors were resistant to chemotherapy based on pathologic downstaging rate (p<0.05). The results from CIBERSORT predicted that the BIE subtype was highly enriched with CD8þ T cells and NK cells (p<0.001).
CONCLUSIONS: Our results reveal the existence of novel basal immune subtypes among patients with muscle invasive bladder cancer with distinct molecular features and clinical outcomes. The clinical implications of these subtypes are the subject of ongoing studies.
